CD274 and non-small cell lung carcinoma: Pivotal studies using nivolumab determined PD-L1 expression ≥1%, ≥5%, and ≥10% as their cut-offs [6, 7], and a study for non-squamous NSCLC has demonstrated significant correlation between PD-L1+ status and clinical efficacy of nivolumab [7].